Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Methylene Blue for Treatment of Hospitalized COVID-19 Patients: A Randomized, Controlled, Open-Label Clinical Trial, Phase 2
Daryoush Hamidi-Alamdari, Saied Hafizi-Lotfabadi, Ahmad Bagheri Moghaddam, et al.
Revista de investigaci�n Cl�nica (2021) Vol. 73, Iss. 3
Open Access | Times Cited: 25

Showing 25 citing articles:

Cytokine Storm in COVID-19: Immunopathogenesis and Therapy
Christian Zanza, Tatsiana Romenskaya, A Manetti, et al.
Medicina (2022) Vol. 58, Iss. 2, pp. 144-144
Open Access | Times Cited: 254
Mesoporous onion-like carbon nanostructures from natural oil for high-performance supercapacitor and electrochemical sensing applications: Insights into the post-synthesis sonochemical treatment on the electrochemical performance
Athiyanam Venkatesan Ramya, Riya Thomas, Manoj Balachandran
Ultrasonics Sonochemistry (2021) Vol. 79, pp. 105767-105767
Open Access | Times Cited: 33
Identification of broad anti-coronavirus chemical agents for repurposing against SARS-CoV-2 and variants of concern
Luca Murer, Romain Volle, Vardan Andriasyan, et al.
Current Research in Virological Science (2022) Vol. 3, pp. 100019-100019
Open Access | Times Cited: 26
Repurposing methylene blue in the management of COVID-19: Mechanistic aspects and clinical investigations
Neha Dabholkar, Srividya Gorantla, Sunil Kumar Dubey, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 142, pp. 112023-112023
Open Access | Times Cited: 32
Methylene blue: a controversial diagnostic acid and medication?
Marek Bužga, Evžen Machytka, Eliška Dvořáčková, et al.
Toxicology Research (2022) Vol. 11, Iss. 5, pp. 711-717
Open Access | Times Cited: 22
A Novel Approach of Combining Methylene Blue Photodynamic Inactivation, Photobiomodulation and Oral Ingested Methylene Blue in COVID-19 Management: A Pilot Clinical Study with 12-Month Follow-Up
Juliette Hepburn, Susan Williams-Lockhart, René‐Jean Bensadoun, et al.
Antioxidants (2022) Vol. 11, Iss. 11, pp. 2211-2211
Open Access | Times Cited: 17
Exploring autophagy in treating SARS-CoV-2 spike protein-related pathology
Matthew Halma, Paul E. Marik, Yusuf M. Saleeby
Endocrine and Metabolic Science (2024) Vol. 14, pp. 100163-100163
Open Access | Times Cited: 3
An Updated Prioritization of Geroscience- Guided FDA-Approved Drugs Repurposed to Target Aging
Michael Leone, Nir Barzilai
Medical Research Archives (2024) Vol. 12, Iss. 2
Open Access | Times Cited: 3
Application of methylene blue for the prevention and treatment of COVID-19: A narrative review.
Elaheh Emadi, Daryoush Hamidi Alamdari, Davood Attaran, et al.
PubMed (2024) Vol. 27, Iss. 7, pp. 780-792
Closed Access | Times Cited: 3
Methylene Blue Is a Nonspecific Protein–Protein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19
Sung-Ting Chuang, Henrietta Papp, Anett Kuczmog, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 5, pp. 621-621
Open Access | Times Cited: 14
Clinical effectiveness and prospects of methylene blue: A systematic review
Assel Seitkazina, Jin-Kyoung Yang, Sehoon Kim
Precision and Future Medicine (2022) Vol. 6, Iss. 4, pp. 193-208
Open Access | Times Cited: 11
In Vitro Evaluation of the Antiviral Activity of Methylene Blue Alone or in Combination against SARS-CoV-2
Mathieu Gendrot, Priscilla Jardot, Océane Delandre, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 14, pp. 3007-3007
Open Access | Times Cited: 12
Antimicrobial Activity of Methylene Blue Associated with Photodynamic Therapy: In Vitro Study in Multi-Species Oral Biofilm
Bruno Bueno‐Silva, Javier Parma-Garcia, Lúcio Frigo, et al.
Pathogens (2024) Vol. 13, Iss. 4, pp. 342-342
Open Access | Times Cited: 1
Methylene Blue Is a Nonspecific Protein-Protein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19
Sung-Ting Chuang, Henrietta Papp, Anett Kuczmog, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 5
The Effect of Methylene Blue and Its Metabolite—Azure I—on Bioenergetic Parameters of Intact Mouse Brain Mitochondria
Artem P. Gureev, Natalia A. Samoylova, Daria V. Potanina, et al.
Biochemistry (Moscow) Supplement Series B Biomedical Chemistry (2022) Vol. 16, Iss. 2, pp. 148-153
Open Access | Times Cited: 5
Toxicity of the spike protein of COVID-19 is a redox shift phenomenon: A novel therapeutic approach
Laurent Schwartz, Manuel Aparicio-Alonso, Marc Henry, et al.
Free Radical Biology and Medicine (2023) Vol. 206, pp. 106-110
Closed Access | Times Cited: 2
Identification of Broad Anti-Coronavirus Chemical Agents for Repurposing Against SARS-CoV-2 and Variants of Concern
Luca Murer, Romain Volle, Vardan Andriasyan, et al.
SSRN Electronic Journal (2021)
Open Access | Times Cited: 4
Effect of methylene blue and its metabolite — azure I — on bioenergetic parameters of intact mice brain mitochondria
Artem P. Gureev, Natalia A. Samoylova, Daria V. Potanina, et al.
Biomeditsinskaya Khimiya (2021) Vol. 67, Iss. 6, pp. 485-490
Open Access | Times Cited: 4
Challenges of consolidating evidence collected during a pandemic and lessons for the future
Ṣẹ̀yẹ Abògúnr̀in, Alex Adelakun, Titilope Akinola, et al.
Current Medical Research and Opinion (2024) Vol. 40, Iss. 8, pp. 1311-1322
Closed Access
Methylene blue for COVID-19 ARDS: insights from a randomized Clinical Trial
Zahra Sadat Sanei, Fatemeh Shahrahmani, Behrooz Khaleghi Manesh, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024)
Closed Access
Effectiveness of Treatments for Long Vax: Protocol for a Prospective Cohort Study (Preprint)
Matthew Halma
(2024)
Closed Access
Spatiotemporal based response for methylene blue removal using surface modified calcium carbonate microspheres coated with Bacillus sp.
Noha M. Deghiedy, Hanan S. El‐Bastawisy, Ola M. Gomaa
RSC Advances (2023) Vol. 13, Iss. 3, pp. 1842-1852
Open Access
Exploring the Anti-Hypoxaemia Effect of Hydromethylthionine: A Prospective Study of Phase 3 Clinical Trial Participants
Mohammad Arastoo, Michael P. Mazanetz, S. K. Miller, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 13747-13747
Open Access
Effects of evidence-based clinical practice guidelines for COVID-19 in health care quality improvements. A third systematic review.
Anggie Ramírez-Morera, Jordan Salazar-Vargas, Ana Rivera Chavarría, et al.
F1000Research (2023) Vol. 12, pp. 1501-1501
Open Access
Crystal structure of methylene blue citrate
Akhmatkhodja N. Yunuskhodjayev, Shokhista F. Iskandarova, Vahobjon Kh. Sabirov
Zeitschrift für Naturforschung B (2022) Vol. 77, Iss. 11-12, pp. 765-772
Closed Access
Page 1

Scroll to top